DiaMedica to Deliver Poster Presentation at World Conference on Clinical Pharmacology and Therapeutics
July 30 2008 - 9:01AM
Marketwired
WINNIPEG, MANITOBA , a drug discovery and development company
focused on novel treatments for Type 2 diabetes, announces that it
will be presenting results of a study at the 9th World Conference
on Clinical Pharmacology and Therapeutics (www.cpt2008.org) in
Quebec City, Canada today.
The presentation, entitled "Reversing Prediabetes Insulin
Resistance by Synergy of Drugs Mimicking a Feeding Signal"
highlights the preclinical data from the Company's lead drug
candidate, DM-71. DM-71 is a novel combination of Bethanechol and
N-Acetyl Cysteine, two compounds with a strong safety profile that
function in a synergistic manner to replace the function of a
parasympathetic nerve signal to the liver. Neither compound is able
to restore insulin sensitivity on its own, but when combined,
insulin sensitivity is restored to near control levels. DiaMedica
has demonstrated in previous preclinical studies that when this
particular nerve signal is impaired it compromises the ability of
insulin to regulate glucose metabolism.
"The preclinical study used a model of diabetes caused by
voluntary consumption of sucrose rather than genetically or
chemically induced diabetes in order to more closely represent the
human disease", stated Dr. Wayne Lautt, Chief Scientific Officer of
DiaMedica. "The study demonstrated that a one time dose of DM-71
can restore the ability to process the nutrients from a meal when
the parasympathetic nerve to the liver is completely dysfunctional.
These results provide the mechanistic understanding for the recent
successful Phase IIa proof of concept clinical trials reported by
DiaMedica".
About DiaMedica
DiaMedica is a biotechnology company developing novel treatments
for various stages of Type 2 diabetes with three clinical stage
products. The Company's lead product, DM-71, demonstrated the
ability to reduce HbA1c levels and weight in a Phase IIa human
trial. DM-83 showed efficacy in reducing insulin levels in a Phase
IIa meal tolerance test. DiaMedica's third clinical stage product
is entering a Phase IIa trial in the second half of 2008. DiaMedica
trades under the symbol "DMA" on the TSX Venture Exchange. For
additional information please visit the Company's website at
www.diamedica.com.
Caution Regarding Forward-Looking Information
Certain statements contained in this press release constitute
forward-looking information within the meaning of applicable
Canadian provincial securities legislation (collectively,
"forward-looking statements"). These forward-looking statements
relate to, among other things, our objectives, goals, targets,
strategies, intentions, plans, beliefs, estimates and outlook,
including, without limitation, our anticipated future operating
results, and can, in some cases, be identified by the use of words
such as "believe," "anticipate," "expect," "intend," "plan,"
"will," "may" and other similar expressions. In addition, any
statements that refer to expectations, projections or other
characterizations of future events or circumstances are
forward-looking statements.
These statements reflect management's current beliefs and are
based on information currently available to management. Certain
material factors or assumptions are applied in making
forward-looking statements, and actual results may differ
materially from those expressed or implied in such statements.
Important factors that could cause actual results to differ
materially from these expectations include, among other things:
DiaMedica's early stage of development, lack of product revenues
and history of operating losses, uncertainties related to clinical
trials and product development, rapid technological change,
uncertainties related to forecasts, competition, potential product
liability, additional financing requirements and access to capital,
unproven markets, supply of raw materials, income tax matters,
management of growth, partnerships for development and
commercialization of technology, effects of insurers' willingness
to pay for products, system failures, dependence on key personnel,
foreign currency risk, risks related to regulatory matters and
risks related to intellectual property and other risks detailed
from time to time in DiaMedica's filings with Canadian securities
regulatory authorities, as well as DiaMedica's ability to
anticipate and manage the risks associated with the foregoing.
Additional information about these factors and about the material
factors or assumptions underlying such forward-looking statements
may be found in the body of this news release, as well as under the
heading "Risk Factors" contained in DiaMedica's final long-form
prospectus dated March 12, 2007. DiaMedica cautions that the
foregoing list of important factors that may affect future results
is not exhaustive. When relying on DiaMedica's forward-looking
statements to make decisions with respect to DiaMedica, investors
and others should carefully consider the foregoing factors and
other uncertainties and potential events.
These risks and uncertainties should be considered carefully and
prospective investors should not place undue reliance on the
forward-looking statements. Although the forward-looking statements
contained in this press release are based upon what management
believes to be reasonable assumptions, DiaMedica cannot provide
assurance that actual results will be consistent with these
forward-looking statements. DiaMedica undertakes no obligation to
update or revise any forward-looking statement.
The TSX Venture Exchange does not accept responsibility for the
adequacy or accuracy of this release.
Contacts: DiaMedica Inc. Kevin Richardson, Ph.D. (204) 478-5605
(204) 453-3745 (FAX) Email: krichardson@diamedica.com Website:
www.diamedica.com
DiaMedica Inc. (TSXV:DMA)
Historical Stock Chart
From Jun 2024 to Jul 2024
DiaMedica Inc. (TSXV:DMA)
Historical Stock Chart
From Jul 2023 to Jul 2024